EA201490415A1 - Композиции наночастица-пептид - Google Patents
Композиции наночастица-пептидInfo
- Publication number
- EA201490415A1 EA201490415A1 EA201490415A EA201490415A EA201490415A1 EA 201490415 A1 EA201490415 A1 EA 201490415A1 EA 201490415 A EA201490415 A EA 201490415A EA 201490415 A EA201490415 A EA 201490415A EA 201490415 A1 EA201490415 A1 EA 201490415A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- nanoparticles
- linker
- amino acid
- acid selected
- peptide portion
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 5
- 239000002105 nanoparticle Substances 0.000 abstract 4
- 239000003446 ligand Substances 0.000 abstract 3
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 125000000837 carbohydrate group Chemical group 0.000 abstract 1
- 230000003834 intracellular effect Effects 0.000 abstract 1
- 239000002184 metal Substances 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 239000004065 semiconductor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
- B82B3/00—Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/77—Ovalbumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Ceramic Engineering (AREA)
- Inorganic Chemistry (AREA)
- Manufacturing & Machinery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Согласно настоящему изобретению предложены наночастицы и композиции, содержащие указанные наночастицы, а также способы внутриклеточной доставки пептидов и способы получения наночастиц и родственных продуктов. Указанные наночастицы содержат ядро, содержащее атом металла и/или полупроводника; и корону, содержащую множество лигандов, ковалентно связанных с ядром, при этом по меньшей мере первый лиганд из указанного множества содержит углеводный фрагмент, который ковалентно связан с ядром через первый линкер, и при этом по меньшей мере второй лиганд из указанного множества содержит выбранный пептид, который ковалентно связан с ядром через второй линкер. Второй линкер содержит пептидную часть и непептидную часть, при этом указанная пептидная часть указанного второго линкера содержит последовательность XXZ, где Xпредставляет собой аминокислоту, выбранную из А и G; Xпредставляет собой аминокислоту, выбранную из А и G; и Zпредставляет собой аминокислоту, выбранную из Y и F.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161531745P | 2011-09-07 | 2011-09-07 | |
PCT/EP2012/067561 WO2013034726A1 (en) | 2011-09-07 | 2012-09-07 | Nanoparticle-peptide compositions |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201490415A1 true EA201490415A1 (ru) | 2014-08-29 |
EA025758B1 EA025758B1 (ru) | 2017-01-30 |
Family
ID=46829760
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201490415A EA025758B1 (ru) | 2011-09-07 | 2012-09-07 | Композиции наночастица-пептид |
Country Status (12)
Country | Link |
---|---|
US (1) | US9598479B2 (ru) |
EP (1) | EP2753360B1 (ru) |
JP (1) | JP6077544B2 (ru) |
KR (1) | KR102001269B1 (ru) |
CN (1) | CN103917249B (ru) |
AU (1) | AU2012306243B2 (ru) |
BR (1) | BR112014005242B1 (ru) |
EA (1) | EA025758B1 (ru) |
ES (1) | ES2627507T3 (ru) |
IN (1) | IN2014MN00433A (ru) |
MX (1) | MX345883B (ru) |
WO (1) | WO2013034726A1 (ru) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9511151B2 (en) | 2010-11-12 | 2016-12-06 | Uti Limited Partnership | Compositions and methods for the prevention and treatment of cancer |
EA201490520A1 (ru) * | 2011-09-07 | 2014-09-30 | Мидатек Лимитед | Противоопухолевые вакцины на основе наночастиц |
US10988516B2 (en) | 2012-03-26 | 2021-04-27 | Uti Limited Partnership | Methods and compositions for treating inflammation |
US9603948B2 (en) | 2012-10-11 | 2017-03-28 | Uti Limited Partnership | Methods and compositions for treating multiple sclerosis and related disorders |
JP2017500285A (ja) | 2013-11-04 | 2017-01-05 | ユーティーアイ リミテッド パートナーシップ | 持続的免疫療法のための方法および組成物 |
CN104225589B (zh) * | 2014-07-25 | 2018-02-09 | 武汉博沃生物科技有限公司 | 一种缀合疫苗及其制备方法 |
CN104189901B (zh) * | 2014-07-25 | 2018-05-01 | 武汉博沃生物科技有限公司 | 一种肺炎球菌缀合疫苗及其制备方法 |
CN107050444B (zh) * | 2014-07-25 | 2020-08-28 | 武汉博沃生物科技有限公司 | 轮状病毒多糖-蛋白结合疫苗及其制备方法 |
KR101694121B1 (ko) | 2014-10-28 | 2017-01-10 | (주)헵틸와이 | 이중 가교구조의 생체친화형 다공성 시트 및 그 제조방법 |
KR20160067472A (ko) | 2014-12-04 | 2016-06-14 | (주)헵틸와이 | 생체친화형 섬유상 매트릭스, 이를 포함하는 마스크 팩 및 그 제조방법 |
US12011480B2 (en) | 2015-05-06 | 2024-06-18 | Uti Limited Partnership | Nanoparticle compositions for sustained therapy |
GB2541166A (en) * | 2015-07-24 | 2017-02-15 | Midatech Ltd | Nanoparticle-based liver-targeting therapy and imaging |
EA201991377A1 (ru) | 2017-01-03 | 2020-01-21 | Эмерджекс Ваксинс Холдинг Лимитед | Композиции универсальной вакцины против гриппа |
KR102015805B1 (ko) * | 2017-05-11 | 2019-08-29 | 서울대학교산학협력단 | 유기 반도체 물질의 자기조립 나노구조체 및 제조방법 |
WO2019058133A2 (en) | 2017-09-21 | 2019-03-28 | Emergex Vaccines Holding Limited | MHC CLASS I ASSOCIATED PEPTIDES FOR THE PREVENTION AND TREATMENT OF ZIKA VIRUS |
EP3735269A1 (en) | 2018-01-06 | 2020-11-11 | Emergex Vaccines Holdings Limited | Mhc class i associated peptides for prevention and treatment of multiple flavi virus |
WO2019186200A1 (en) | 2018-03-29 | 2019-10-03 | Emergex Vaccines Holding Limited | Vaccine compositions |
EP3773705A1 (en) | 2018-03-29 | 2021-02-17 | Emergex Vaccines Holdings Limited | Vaccine compositions |
SG11202011122XA (en) | 2018-05-18 | 2020-12-30 | Emergex Vaccines Holding Ltd | Reverse peptide vaccine |
RU2695135C1 (ru) * | 2018-07-11 | 2019-07-22 | Федеральное государственное унитарное предприятие "Научно-исследовательский институт гигиены, профпатологии и экологии человека" Федерального медико-биологического агентства | Двухуровневая микрогранулированная форма терапевтического пептида для перорального применения и способ ее получения |
GB201820470D0 (en) * | 2018-12-14 | 2019-01-30 | Midatech Ltd | Antifolate-carrying nanoparticles and their use in medicine |
GB201820471D0 (en) * | 2018-12-14 | 2019-01-30 | Midatech Ltd | Nanoparticle-based therapy of inflammatory disorders |
EP3909612A1 (en) | 2020-05-12 | 2021-11-17 | Life Science Inkubator Betriebs GmbH & Co. KG | Composition of nanoparticles |
GB202008250D0 (en) | 2020-06-02 | 2020-07-15 | Emergex Vaccines Holding Ltd | Diagnosis, prevention and treatment of coronavirus infection |
EP4294435A1 (en) | 2021-02-16 | 2023-12-27 | Emergex Vaccines Holding Limited | Reverse peptides from coronavirus for immunogenic purposes |
CN113209046B (zh) * | 2021-05-08 | 2022-09-09 | 中国人民解放军陆军军医大学 | 一种CoSe@BSA纳米粒子药物组合物及其制备方法和应用 |
WO2022253917A1 (en) | 2021-06-02 | 2022-12-08 | Emergex Vaccines Holding Limited | Human coronavirus 229e derived peptides |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050100928A1 (en) * | 1999-09-16 | 2005-05-12 | Zycos Inc., A Delaware Corporation | Nucleic acids encoding polyepitope polypeptides |
GB0025414D0 (en) | 2000-10-16 | 2000-11-29 | Consejo Superior Investigacion | Nanoparticles |
GB0313259D0 (en) | 2003-06-09 | 2003-07-16 | Consejo Superior Investigacion | Magnetic nanoparticles |
IL158140A0 (en) * | 2003-09-25 | 2004-03-28 | Hadasit Med Res Service | Multiepitope polypeptides for cancer immunotherapy |
ES2242528B1 (es) | 2004-03-25 | 2006-12-01 | Consejo Sup. Investig. Cientificas | Nanoparticulas magneticas de metales nobles. |
EP2330208B1 (en) | 2004-05-24 | 2017-10-18 | Midatech Ltd. | Nanoparticles comprising RNA ligands |
CN101123990A (zh) * | 2004-10-01 | 2008-02-13 | Mida科技有限公司 | 包含抗原和佐剂的纳米颗粒,和免疫原性结构 |
CA2582668C (en) * | 2004-10-01 | 2013-10-01 | Midatech Ltd | Nanoparticles comprising antigens and adjuvants, and immunogenic structures |
CA2617869C (en) * | 2005-08-04 | 2017-02-14 | Thomas William Rademacher | Nanoparticles comprising antibacterial ligands |
ATE517613T1 (de) * | 2006-04-13 | 2011-08-15 | Midatech Ltd | Nanoteilchen mit drei verschiedenen liganden zur auslösung einer immunantwort gegen infektiöse mittel |
EP2161279A1 (en) | 2008-08-29 | 2010-03-10 | Centre National de la Recherche Scientifique | Synthetic peptides corresponding to overlapping neutralizing determinants in the CBD1 epitope induce broadly neutralizing antibodies |
US8343497B2 (en) * | 2008-10-12 | 2013-01-01 | The Brigham And Women's Hospital, Inc. | Targeting of antigen presenting cells with immunonanotherapeutics |
US9764012B2 (en) * | 2009-04-01 | 2017-09-19 | University Of Miami | Vaccine compositions and methods of use thereof |
EP2470200B1 (en) | 2009-08-26 | 2017-03-15 | Immunotope, Inc. | Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
EP2305310A1 (en) | 2009-09-25 | 2011-04-06 | Asociación Centro de Investigación Cooperativa en Biomateriales - CIC biomaGUNE | Gold -coated magnetic glyconanoparticles functionalised with proteins for use as diagnostic and therapeutic agents |
TWI485245B (zh) | 2010-01-25 | 2015-05-21 | Oncotherapy Science Inc | 經修飾之melk胜肽及含此胜肽之疫苗 |
EA201490520A1 (ru) * | 2011-09-07 | 2014-09-30 | Мидатек Лимитед | Противоопухолевые вакцины на основе наночастиц |
-
2012
- 2012-09-07 IN IN433MUN2014 patent/IN2014MN00433A/en unknown
- 2012-09-07 ES ES12756725.3T patent/ES2627507T3/es active Active
- 2012-09-07 US US14/343,083 patent/US9598479B2/en active Active
- 2012-09-07 CN CN201280049979.0A patent/CN103917249B/zh active Active
- 2012-09-07 JP JP2014529001A patent/JP6077544B2/ja active Active
- 2012-09-07 WO PCT/EP2012/067561 patent/WO2013034726A1/en active Application Filing
- 2012-09-07 EP EP12756725.3A patent/EP2753360B1/en active Active
- 2012-09-07 KR KR1020147009090A patent/KR102001269B1/ko active IP Right Grant
- 2012-09-07 AU AU2012306243A patent/AU2012306243B2/en active Active
- 2012-09-07 MX MX2014002418A patent/MX345883B/es active IP Right Grant
- 2012-09-07 BR BR112014005242-5A patent/BR112014005242B1/pt active IP Right Grant
- 2012-09-07 EA EA201490415A patent/EA025758B1/ru not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP2753360A1 (en) | 2014-07-16 |
MX2014002418A (es) | 2014-10-13 |
EA025758B1 (ru) | 2017-01-30 |
CN103917249B (zh) | 2016-11-09 |
AU2012306243B2 (en) | 2016-10-20 |
IN2014MN00433A (ru) | 2015-06-19 |
BR112014005242A2 (pt) | 2018-06-05 |
MX345883B (es) | 2017-02-22 |
WO2013034726A1 (en) | 2013-03-14 |
EP2753360B1 (en) | 2017-04-26 |
AU2012306243A1 (en) | 2014-03-13 |
ES2627507T3 (es) | 2017-07-28 |
KR20140069101A (ko) | 2014-06-09 |
JP6077544B2 (ja) | 2017-02-08 |
US9598479B2 (en) | 2017-03-21 |
KR102001269B1 (ko) | 2019-07-17 |
CN103917249A (zh) | 2014-07-09 |
BR112014005242B1 (pt) | 2022-07-26 |
US20140341938A1 (en) | 2014-11-20 |
JP2014527960A (ja) | 2014-10-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201490415A1 (ru) | Композиции наночастица-пептид | |
AU2020202093A1 (en) | Oligonucleotide-ligand conjugates and process for their preparation | |
CY1125652T1 (el) | Αντι-pdi αντισωματα και η χρηση τους ως θεραπευτικοι και διαγνωστικοι παραγοντες | |
CY1122278T1 (el) | Αντι il-36r αντισωματα | |
PH12015502180A1 (en) | Wt1-antigen peptide conjugate vaccine | |
MX355255B (es) | Variantes de fc y métodos para su producción. | |
EP4329431A3 (en) | Novel heteroleptic iridium complexes | |
EA201490756A1 (ru) | Разагилина цитрамид | |
MX346731B (es) | Producción de proteínas heteromultiméricas. | |
EA201590986A1 (ru) | Антитела к ceacam5 и их применения | |
EA201490677A1 (ru) | Связывающие антиген cd27l белки | |
EA201490039A1 (ru) | Химерные и гибридные полипептиды фактора viii и способы их применения | |
MX2015011830A (es) | Metodos de fabricacion y sintesis de grupos de enlace de aminoacidos conjugados con compuestos usados para la obtencion de imagenes dirigida de los tumores. | |
UA115657C2 (uk) | Виділене антитіло, яке зв'язується з одним або декількома епітопами тау, фармацевтична композиція, що його містить, спосіб лікування та спосіб діагностики хвороби альцгеймера на основі виділеного антитіла | |
EA201000207A1 (ru) | Новые иммуногенные эпитопы для иммунотерапии | |
PH12014502010A1 (en) | Bispecific antibodies against human tweak and human il17 and uses thereof | |
WO2012115863A3 (en) | Hybrid stitching | |
CY1122980T1 (el) | Φαρμακευτικο σκευασμα που περιεχει ινοσιτολη | |
EA201490520A1 (ru) | Противоопухолевые вакцины на основе наночастиц | |
PH12015500644B1 (en) | Novel rig-i ligands and methods for producing them | |
CO6640211A2 (es) | Composiciones del péptido a-beta y métodos | |
UA117097C2 (uk) | Антитіло проти лігандів рецептора в1 брадикініну | |
CR11396A (es) | Nuevos anticuerpos especificos de los peptidos-b-amiloides y sus usos como agentes de diagnostico o drogas | |
EA201391265A1 (ru) | Амиды индолкарбоновых и бензимидазолкарбоновых кислот в качестве инсектицидов и акарицидов | |
EP3747891A3 (en) | Compositions and methods for conjugating oligonucleotides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG TJ TM |